Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients

Name: Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients
Creator: Maria Espinosa
Published: 2020-03-19T13:04:10.904Z
Keywords: Dermatology

Espinosa, Maria; Nguyen, Morgan; Saenz Aguirre, Amaia; Martinez-Escala, Maria Estela; Kim, Jane; Walker, Christina; Pontes, David; Silverberg, Jonathan; Choi, Jaehyuk; Pro, Barbara; Pincus, Laura; Guitart, Joan; Zhou, Xiaolong

doi:10.17632/79dp7449jw.1

Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients

Published: 19 March 2020| Version 1 | DOI: 10.17632/79dp7449jw.1

Contributors:

Maria Espinosa,

Morgan Nguyen,

Amaia Saenz Aguirre,

Maria Estela Martinez-Escala,

Jane Kim,

Christina Walker,

David Pontes,

Jonathan Silverberg,

Jaehyuk Choi,

Barbara Pro,

Laura Pincus,

Joan Guitart,

Xiaolong Zhou

Description

Supplement 1: Report of Cases Seven patients were prescribed dupilumab for chronic recalcitrant presumed AD (cases 1-4), or as an off-label treatment for patients with MF and severe pruritus (cases 5-7). In all 7 patients, the standard dosing regimen for dupilumab was followed (600mg loading dose, followed by 300mg every 2 weeks subcutaneously). Case vignettes and photographs found below.

Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients

Description

Files